InMode's steady revenue trajectory amid acquisition uncertainty signals continued device-market strength despite M&A noise.
InMode has guided Q2 2026 revenue to $95.2–$95.4 million and reiterated full-year 2026 guidance of $365–$375 million, representing mid-to-high single-digit growth. The company will report August 5. The guidance holds despite the Steel Partners acquisition proposal and broader market volatility, suggesting stable demand for Morpheus8 and Evolab across U.S. and international markets.
InMode's revenue mix remains tilted toward RF microneedling (Morpheus8 dominates fractional RF adoption in U.S. medspas) and laser platforms. Steady guidance implies that practice acquisition patterns and per-unit pricing have not materially shifted. The company's installed base continues to expand, particularly among independent medspas and DSOs seeking differentiated body-contouring and skin-resurfacing capability.
InMode guides Q2 at $95.2–$95.4M and reiterates FY 2026 at $365–$375M amid acquisition uncertainty.
For practice owners, InMode's stable trajectory suggests the device market is not contracting despite competitive pressure from Cynosure, Cutera, and Chinese OEMs. Morpheus8 placement velocity and pricing remain intact. The August 5 call will clarify whether the acquisition proposal affects guidance or capital allocation.
Source: original report ↗
Frequently asked questions
What is InMode's Q2 2026 revenue guidance and full-year outlook?
InMode has guided Q2 2026 revenue to $95.2–$95.4 million and reiterated full-year 2026 guidance of $365–$375 million, representing mid-to-high single-digit growth. The company will report results on August 5.
Is Morpheus8 still the dominant RF microneedling device in medspas?
Yes, Morpheus8 dominates fractional RF adoption in U.S. medspas and remains InMode's core revenue driver. Steady guidance indicates placement velocity and per-unit pricing have not materially shifted despite competitive pressure.
How is the Steel Partners acquisition affecting InMode's business guidance?
InMode has maintained its revenue guidance despite the Steel Partners acquisition proposal and broader market volatility, suggesting the deal uncertainty has not impacted near-term demand or capital allocation decisions. The August 5 earnings call will provide clarity on whether the acquisition affects future guidance.
What is driving InMode's revenue growth in 2026?
Continued expansion of the installed base among independent medspas and DSOs seeking differentiated body-contouring and skin-resurfacing capability is driving growth. Revenue remains tilted toward RF microneedling (Morpheus8) and laser platforms across U.S. and international markets.
Is the medispa device market contracting amid competition from Cynosure and Cutera?
No, InMode's stable guidance suggests the device market is not contracting despite competitive pressure from Cynosure, Cutera, and Chinese OEMs. Morpheus8 placement velocity and pricing remain intact, indicating sustained demand for differentiated platforms.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
